Skip to Main content Skip to Navigation
Journal articles

Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine

Abstract : SARS-CoV-2 infection leads to a highly variable clinical evolution, ranging from asymptomatic to severe disease with acute respiratory distress syndrome, requiring intensive care units (ICU) admission. The optimal management of hospitalized patients has become a worldwide concern and identification of immune biomarkers predictive of the clinical outcome for hospitalized patients remains a major challenge. Immunophenotyping and transcriptomic analysis of hospitalized COVID-19 patients at admission allow identifying the two categories of patients. Inflammation, high neutrophil activation, dysfunctional monocytic response and a strongly impaired adaptive immune response was observed in patients who will experience the more severe form of the disease. This observation was validated in an independent cohort of patients. Using in silico analysis on drug signature database, we identify differential therapeutics that specifically correspond to each group of patients. From this signature, we propose a score—the SARS-Score—composed of easily quantifiable biomarkers, to classify hospitalized patients upon arrival to adapt treatment according to their immune profile.
Complete list of metadata
Contributor : Gestionnaire Hal-Su Connect in order to contact the contributor
Submitted on : Wednesday, September 15, 2021 - 3:49:14 PM
Last modification on : Tuesday, October 19, 2021 - 11:40:53 AM


Publication funded by an institution




Jules Russick, Pierre-Emmanuel Foy, Nathalie Josseaume, Maxime Meylan, Nadine Hamouda, et al.. Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine. Frontiers in Immunology, Frontiers, 2021, 12, pp.701273. ⟨10.3389/fimmu.2021.701273⟩. ⟨hal-03345484⟩



Record views


Files downloads